Dr. Peter Meintjes joins Transplant Genomics as CCO | State

MANSFIELD, Mass., April 29, 2020 /PRNewswire/ — Eurofins -Transplant Genomics, Inc. (“TGI”), announce that Dr. Peter Meintjes will be part of the corporate as Chief Business Officer to guide the commercialization of TruGraf®, the one blood check permitted by CMS for surveillance to rule out “silent” subclinical acute rejection in kidney transplant recipients with secure graft perform.

Dr. Meintjes joins TGI after six years at Omixon, world chief in pre-transplant HLA Typing, the place he departs as CEO, having grown the corporate at a CAGR of >75% since its first full 12 months of operation as a molecular diagnostics firm. Dr. Meintjes was drawn to TGI by the distinctive alternative of commercializing TruGraf, a non-invasive blood check, with established reimbursement that may verify the absence of “silent” subclinical acute rejection in kidney transplant recipients with secure renal perform. TruGraf is considerably differentiated compared with present donor derived cell-free DNA (ddcfDNA) and creatinine/eGFR post-transplant kidney monitoring exams, that are solely able to confirming lively rejection in already injured kidneys, with out secure graft perform.

Dr. Meintjes joins Founder and CEO Dr. Stan Rose, who has led TGI by receiving a Native Protection Dedication (LCD) for TruGraf in November 2019. TruGraf additionally advantages from the potential CTOT-08 research, which demonstrated the prevalent incidence of silent subclinical rejection and the significance of early detection and remedy to long term outcomes. The medical utility and validity of TruGraf have been established through the use of paired non-invasive liquid biopsies (blood samples) and invasive tissue biopsies (present gold customary for ruling out silent rejection) which demonstrated a 94% concordance. This highlights how TruGraf is the one check that can be utilized for routine surveillance to handle two vital unmet medical wants for kidney transplant recipients:

1. ~35% of sufferers with secure graft perform over two years are literally “silently” rejecting, and go untreated by ready for proof of medical acute rejection (i.e. elevated creatinine or ddcfDNA), indicating harm already executed, and resulting in worse outcomes for sufferers
2. ~75% of sufferers present process invasive surveillance biopsies weren’t experiencing any type of rejection, placing sufferers at pointless dangers from these invasive procedures

Through the use of TruGraf, nephrologists are empowered to make higher remedy choices for his or her sufferers.  On the similar time, sufferers who check damaging are comforted by studying that they’ve satisfactory immune suppression (i.e. immune quiescence, graft stability, wholesome kidneys) with out having to be subjected to dangerous, expensive and painful biopsies.

With the sources of father or mother firm Eurofins, TGI is positioning for robust progress into the post-transplant kidney testing market after glorious adoption amongst early clients. TGI is hiring extra gross sales, medical science liaisons and advertising personnel to assist the business enlargement.

MEDIA CONTACTS:
Darren Lee, Vice President Transplant Advertising
Eurofins U.S. Medical Diagnostics 
508-337-6200 or DarrenLee@EurofinsUS.com

About Eurofins – Transplant Genomics
Eurofins – Transplant Genomics (“TGI”) is a molecular diagnostics firm dedicated to bettering organ transplant outcomes, with an preliminary concentrate on kidney transplant recipients. Working with the transplant neighborhood, TGI is commercializing a set of exams enabling analysis and prediction of transplant recipient immune standing. Check outcomes will assist clinicians with info to optimize immune-suppressive remedy, improve affected person care and enhance graft survival. Check providers are provided by TGI’s CLIA laboratory in Fremont, CA. 

Eurofins – a worldwide chief in bio-analysis
Eurofins Scientific by its subsidiaries (hereinafter typically “Eurofins” or “the Group”) believes it’s a scientific chief in meals, atmosphere, pharmaceutical and cosmetics merchandise testing and in agroscience CRO providers. It’s also one of many international impartial market leaders in sure testing and laboratory providers for genomics, discovery pharmacology, forensics, CDMO, superior materials sciences and for supporting medical research. As well as, Eurofins is without doubt one of the main international rising gamers in specialty medical diagnostic testing. With about 45,000 employees in additional than 800 laboratories throughout 47 nations, Eurofins presents a portfolio of over 200,000 analytical strategies for evaluating the security, id, composition, authenticity, origin and purity of organic substances and merchandise, in addition to for revolutionary medical diagnostic. The Group goal is to supply its clients with high-quality providers, correct outcomes on time and skilled recommendation by its extremely certified employees.

Eurofins is dedicated to pursuing its dynamic progress technique by increasing each its know-how portfolio and its geographic attain. By R&D and acquisitions, the Group attracts on the most recent developments within the subject of biotechnology and analytical chemistry to supply its purchasers distinctive analytical options and probably the most complete vary of testing strategies.

As some of the revolutionary and high quality oriented worldwide gamers in its business, Eurofins is ideally positioned to assist its purchasers’ more and more stringent high quality and security requirements and the increasing calls for of regulatory authorities all over the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Inventory Alternate (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Necessary disclaimer:

This press launch incorporates forward-looking statements and estimates that contain dangers and uncertainties. The forward-looking statements and estimates contained herein symbolize the judgment of Eurofins Scientific’s administration as of the date of this launch. These forward-looking statements usually are not ensures for future efficiency, and the forward-looking occasions mentioned on this launch could not happen. Eurofins Scientific disclaims any intent or obligation to replace any of those forward-looking statements and estimates. All statements and estimates are made primarily based on the knowledge obtainable to the Firm’s administration as of the date of publication, however no assure might be made as to their validity.